Orgovyx (Relugolix) Patent Expiration, LOE Window & CMS Spending

Orgovyx (Relugolix) by Sumitomo America: FDA Orange Book core substance LOE 2033-09-27 (last listed 2037-09-29), 0 AB generics, $497.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSumitomo America
FDA Application & PathwayN214621 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-09-27
Last Listed Patent or Exclusivity Date2037-09-29
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$497.0M
2024 Medicare Part D Spend$484.3M
2024 Medicaid Spend$12.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.